Adherence to treatment plans is essential to optimize clinical outcomes for patients with chronic conditions. SPUR is a unique adherence solution that provides an individual behavioral diagnosis and intervention plan for each patient.
Integration addresses critical need for accurate, real-time automated insulin delivery data in Type 1 Diabetes clinical research
GlucoseReady™ selected as finalist for “Best Digital Health Solution”.
Members from multiple therapeutic areas will incorporate the patient voice into clinical trial technology design.
AI tool provides real time eCOA and connected device operational data insights.
Industry-leading behavioral science tool SPUR™ is validated to predict adherence and will be offered through the Clinical ink technology platform
Clinical ink, a global life science technology company, announces the promotion of John Pappadakis from EVP, Global Business Development to Chief Commercial Officer and Megan Petrylak from EVP, Clinical Operations to Chief Operating Officer.
Clinical ink announces EDCXtra: An integrated web-based EDC, DDC and eCOA platform.
Clinical ink announces EDCXtra™ : An integrated web-based EDC, DDC and eCOA platform Read More...
Clinical ink announced the appointment of Dr. Nicholas Alp as Chief Medical Officer will lead the creation of innovative solutions and commercial strategies for clinical trial technology based on his experience as an interventional cardiologist and clinical trialist.
Clinical ink Appoints Dr. Nicholas Alp, MD PhD as Chief Medical Officer Read More...
Clinical ink announces an integrated suite of eClinical tools for cardiometabolic clinical trials.
Clinical ink announces GlucoseReady™ Read More...
Clinical ink is expanding its patient engagement suite with the inclusion of the SPUR™ behavioral diagnostic tool created by Observia.
Clinical ink Expands Patient Engagement Solutions with Behavioral Diagnostic Tool SPUR™ Read More...
Clinical ink is setting a new industry benchmark in advancing study build timelines. Harnessing the power of the latest eCOA technology, Clinical ink can now reduce study build timelines to as little as 10 days.
Sales and Solutions
Direct 1.336.464.0697
Support
Toll-Free 1.877.254-8307
Direct 1.336.464.0697
Insert HTML text here.
Request more information, submit questions, set up a demonstration, and more.
